EP1416950A1

EP1416950A1 - Artichoke leaf extracts

Info

Publication number: EP1416950A1
Application number: EP02794577A
Authority: EP
Inventors: Jürgen EICH; Thomas Haffner; Thomas Goerke; Werner Schneider
Original assignee: Lichtwer Pharma AG
Current assignee: DIVAPHARMA CHUR AG
Priority date: 2001-08-08
Filing date: 2002-08-07
Publication date: 2004-05-12
Also published as: WO2003013562A1; MXPA04001115A; HUP0600153A2; YU12404A; US20040234674A1; CA2455761A1; NO20040979L; HRP20040225A2; HRPK20040225B3; IL160083A; PL205013B1; DE10164893B4; PL368184A1; IL160083A0; JP2004537578A; HUP0600153A3; DE10138929A1

Abstract

The invention relates to artichoke leaf extracts (Cynarae folium) that are characterized by defined absolute percentages and relative inherent percentages of typical constituents of artichoke leaves such as caffeoyl quinic acids and flavonoids The activity spectrum of the inventive leaf extracts is substantially different from known artichoke leaf extracts, said inventive leaf extracts also being different from each other. The invention also relates to methods for producing the extracts and to fields of application thereof.

Description

Artichoke leaves extracts

description

The invention relates to ^'extracts from artichoke leaves (folium Cynarae), processes for their preparation and their use in various application fields.

State of the art

Preparations made from artichoke leaves (Cynara scolymus L.) are widely used in the treatment of functional dyspeptic complaints. Press juices from fresh leaves and genuine aqueous and aqueous / alcoholic extracts (primary extracts) from fresh and dried leaves are used.

The choleretic (bile flow-promoting) effect, the main active principle for the treatment of functional dyspepsia, could be clearly demonstrated for aqueous or alcoholic / aqueous primary extracts with the aid of in vitro and in vivo experiments and is considered scientifically proven (Brand N. monograph Cynara. In : Hansel R, Keller K, Rimpler H, Schneider G (ed.): Hager's Handbook of Pharmaceutical Practice. 5th Edition, Volume 4: Drugs AD. Springer Verlag, Berlin, Heidelberg, New York 1992: 1117-1122 ; BRAND N. Zeitschr Phytother _1999/20:... 292-302] These extracts are officially recognized in the treatment of dyspeptic symptoms (preparation monograph for Cynarae folium, artichoke leaves, BAnz 122, 6.7.1988, in the corrected version of the BAnz 164 01.09.1990).

With regard to the effects mentioned, the following classes of ingredients of artichoke leaves and their extracts as specific lead substances and potential

Active substances discussed: 1. Mono-, Di-Caffeoylchinasauren (CCS) and 2. Flavonoide. It can be assumed that further, as yet unidentified compounds, May have shares in the pharmacological and clinical spectrum of activity of artichoke extracts and extract fractions. The individual mono- and di-CCS and the flavonoids from artichoke leaves and their extracts can be separated and quantified using an analytical RP-HPLC gradient method (BRAND and WESCHTA 1991, Zeitschrift. Phytother. 1991; 12: 15-21). Four mono- and up to five di-CCS isomers and at least two flavonoids can be identified in the HPLC fingerprint chromatogram of aqueous artichoke leaf extracts. In this analytical method, the more hydrophilic mono-CCS elute first, followed by cynarin (1,5-di-CCS) and two to three flavone glycosides. This is followed by the remaining more lipophilic di-CCS and, possibly, in smaller amounts, further flavone glycosides and flavone aglycons

(Illustration 1) . The ingredient classes are usually quantified by summation, the CCS content being calculated as chlorogenic acid (= mono-CCS) and the flavonoid content being calculated as luteolin-7-glucoside (= cynaroside).

In addition to the main active principle of "increased choleresis", there are indications for artichoke leaf extracts of anticholestatic, antioxidative and cell stimulating and cell protective effects as well as the beneficial influence on lipid metabolism. These were obtained through in vitro, animal and human pharmacological and clinical examinations (BRAND N. Zeitschrift. Phytother. 1999; 20: 292-302; BRAND N. monograph Cynara. In: HANSEL R, KELLER K, RIMPLER H, SCHNEIDER G (Ed.): Hager "s Handbuch der Pharmaceutischen Praxis. 5th ed., Volume 4: Drugs AD. Springer Verlag,

Berlin, Heidelberg, New York 1992: 1117-1122; EP-A-0958 828).

There are also data on the effectiveness of artichoke leaf extracts in lowering blood serum levels of glucose, creatinine and bilirubin, on immune stimulation and therapy for leukocytopenia, granulocytopenia, lymphocytopenia and Bone marrow damage for the treatment of diabetes and radiation or cytostatics damage to tumor therapy (DE-A-196 27 376; WO 98/01143; DE-A-198 50 543).

In vitro studies of aqueous artichoke leaf primary extracts on rat hepatocytes and human HepG2 cells (hepatocytes) show a moderate, concentration-dependent inhibition of cholesterol biosynthesis, caused by an indirect inhibition of HMG-CoA reductase, the key enzyme of endogenous cholesterol biosynthesis. For watery

Artichoke leaf primary extracts have been clinically proven to have moderate efficacy for lowering cholesterol and LDL values as well as a positive influence on the HDL / LDL ratio (FINTELMANN VZ Allg. Med. 1996; 72: 48-57; KRAFT K. et al. Phytomedicine 1997; 4: 369-378;

ENGLISH W. et al. Pharm. -Forsch. / Drug Res. 2000; 50: 260-265; SIEDEK H. et al. Wiener clinical weekly 1963; 75: 460-463; SCHÖNHOLZER G. Swiss weekly medical journal 1939; 69: 1288-1290). Luteol glycosides as well as free luteolin and 1, 5-dicaffeoylquinic acid (cynarin) from the primary extracts were identified as artichoke leaf ingredients with an inhibitory influence on the activity of the HMG-CoA reductase with the aid of in vitro experiments on hepatocytes. The effect of these compounds when used in human therapy is however not clear (GEBHARDT RJ Pharmacol. Exp. Therap. 1998; 286: 1122-1128; GEHARDT R. Phytotherap. Res. 2001; 15: 1-5; GEBHARDT R. Medwelt 1995; 46 : 348-350; EP 0 807 435 A2; Mars G. et al. Med. Welt 1974; 25: 1572-1574; PRISTAUTZ H. Wiener Med. Wochenzeitschr. 1975; 49: 705-709).

Pharmacological effects have been demonstrated for the above-mentioned and other isolated individual compounds from artichoke leaf extracts, which suggest reasonable indications of therapeutic applications in the indications mentioned above and below (BRAND N. Zeitschrift. Phytother. 1999; 20: 292-302; BRAND N. Monographie Cynara , In: HANSEL R, KELLER K, RIMPLER H, SCHNEIDER G (ed.): Hager ^e s Handbuch der Pharmaceutical Praxis. 5th ed., Volume 4: Drugs AD. Springer Verlag, Berlin, Heidelberg, New York 1992: 1117-1122; EP-A-0958 828). To date, none of the isolated substances has been used for human therapy.

In summary, it can be stated that for primary artichoke leaf extracts a variety of very different areas of application, such as Applications in gastrointestinal diseases (e.g. dyspepsia), disturbed fat metabolism, to increase cell protection in diabetics and tumor patients and for immune stimulation have been described. However, the large number of application areas also results in an undesirable property of primary artichoke leaf extracts, since targeted therapy of defined diseases cannot take place in other areas of the organism without side effects.

Artichoke leaf preparations on the market contain only primary artichoke leaf extracts with the complex pharmacological and clinical activity profile described above, but no "special extracts" with "limited" activity for targeted side effect-free therapies (BRAND N. Zeitschrift. Phytother. 1999; 20: 292-302) , The prior art includes pressed juices, primary aqueous, methanolic and ethanolic extracts, of which the essentially only aqueous extracts in the form of dry extracts are primarily used commercially in solid dosage forms (Table 1). In addition, ethanolic extracts are used in liquid preparations (drops, juices). However, they play a subordinate role in their distribution.

Primary extracts are usually produced by exhaustive extraction of the fresh or dried leaves at elevated temperature. When extracting with Water is usually required for one part of extract 3 - 8 parts of drug, or 20 - 40 parts of fresh leaves (water content of the fresh leaves: 80 - 90%). The extract yield depends on the quality of the leaves, the extraction conditions and the extracting agent used.

CCS levels below 6% for primary aqueous extracts can be considered as prior art. Of these, 55 to 69% are mono-CCS and 31 to 45% di-CCS. The flavonoid content of aqueous primary extracts is between 0.1% and 1% depending on the drug quality (Table 1).

Table 1: Total CCS and flavonoid contents as well as proportions of mono-, di-CCS- in the total CCS content in aqueous artichoke leaf dry extracts from commercial preparations (BRAND DAZ 1997; 137: 60-76) and own results according to standard procedures.

* own results according to standard procedures ** commercial preparations (according to BRAND DAZ 1997; 137: 60- ^■ 76)

In summary, it can be stated that extraction with water or aqueous alcohols results in a quantitative enrichment of the CCS and flavonoids in the extract. The relative ratios of the connections to each other, however, remain practically unchanged. From this it can be concluded that the well-known complex pharmacological / clinical effect profile should be qualitatively identical for both the starting drugs and the aqueous or aqueous / alcoholic extracts produced from them. Only the potency should be a function of the concentration of the compounds analyzed.

The object of the present invention is to separate the different, in part divergent, activity profiles of aqueous or alcoholic / aqueous primary extracts from one another in order to ensure targeted therapeutic use without undesirable side effects (e.g. a lipid-lowering effect without antidyspeptic effect or vice versa). For this purpose, primary extracts are separated by the method according to the invention into two extract fractions A and B, which have a different spectrum of activity. Extract fraction A has a lipid-lowering and cell-protective (antioxidative) effect and an antidyspeptic effect that is no longer present with the primary extract.

Extract fraction B is a significantly more effective antidyspeptic than the primary extract, but has almost no lipid / cholesterol-lowering properties. Another object is to provide methods for making these extract fractions.

Summary of the invention

A first aspect of the invention relates to an extract of artichoke leaves (Cynarae folium), comprising:

A total CCS content of mono-CCS and di-CCS of at least 6%, preferably 10 to 50% based on the total amount of the extract and a flavonoid content of at least 3%, for example 4%, preferably 7 to 30% on the total amount of the extract. According to a preferred form, the extract according to the invention has a proportion of mono-CCS below 30%, for example from 3 to 30%, more preferably from 10 to 30% based on the total CCS content, in a further preferred form the ratio of mono-CCS content to flavonoid content is less than 1.

This extract according to the invention can be obtained by a process for producing an above extract from artichoke leaves (Cynarae folium), comprising the steps:

Liquid-liquid extraction of a primary extract from fresh or dried artichoke leaves, obtained by extraction with water or by extraction with an organic solvent from the series of alcohols, ketones, esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a organic

Solvents from the series of alcohols, ketones, esters, ethers, aro aten or mixture of these compounds, and

- Obtaining the organic phase.

In particular, a mixture of 2-butanol and ethyl acetate is used according to the invention.

In a preferred embodiment, the following steps precede the method according to the invention:

Concentrate the primary extract volume or add water to the primary extract until the extract is over 50%

Contains water.

Washing the extract with a non-polar, water-immiscible solvent, preferably one from the series of alkanes, alkenes, ethers, esters or chlorinated hydrocarbons; Separation and discarding of the organic phase.

In a second aspect of this invention, an extract of artichoke leaves (Cynarae folium) is provided, comprising:

A total CCS content of mono-CCS and di-CCS of at least 1%, preferably 2-15% based on the total amount of the extract, a flavonoid content of at most 2%, preferably 0.02-1.5% on the total amount of the extract and a proportion of mono-CCS of at least 70%, e.g. 75%, based on the total CCS content. The ratio of mono-CCS content to flavonoid content is preferably between 4 and 35, e.g. between 5 and 35.

This extract above can be done by the following

Artichoke leaf (Cynarae folium) method comprising the steps:

Liquid-liquid extraction of a primary extract from fresh or dried artichoke leaves, obtained by extraction with water or by extraction with an organic solvent from the series of alcohols, ketones, esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a organic solvents from the

Series of alcohols, ketones, esters, ethers, aromatics or mixtures of these compounds, and

Extracting the aqueous phase.

In preferred embodiments, the organic solvent for extracting the primary extract is a mixture of 2-butanol and ethyl acetate, the following steps can also be carried out before the process: Concentrate the primary extract volume, or add water to the primary extract until the extract contains over 50% water.

The above extracts can be used in the manufacture of drugs, foods, dietetic foods and cosmetics.

According to the invention, the first-mentioned extracts have an antioxidative, cell- and organ-protective effect and can be used for the treatment and prophylaxis of hypercholesterolemia and hyperlipidemia, for the treatment and prophylaxis of cardiovascular diseases and atherosclerosis and dementias.

The extracts according to the second aspect of the present invention have an antiserotonergic, spasmolytic, anticholestatic, choleretic, antiemetic, prokinetic effect and can be used to increase vesicular secretion and fat digestion, to treat dyspepsia and to treat IBS (Irritable Bowl Syndrome) become.

Both extracts are characterized by the fact that they show the corresponding effects without the undesirable side effects.

Brief description of the figure

FIG. 1 shows a typical RP-HPLC chromatogram of an aqueous, primary artichoke leaf dry extract Detailed description of the invention

The invention is based on the surprising finding that aqueous or aqueous / alcoholic primary extracts according to the invention by extractive liquid-liquid

Fractionation with non-aqueous extracting agents such as organic solvents such as alcohols, ketones, esters, ethers, aromatics e.g. aliphatic alcohols or carboxylic acid esters or mixtures thereof, can be separated into two different fractions. Both

For example, fractions differ significantly with regard to the absolute and relative content of mono-CCS, di-CCS and flavonoids and because of their pharmacological activity profile. The extract components, which can be obtained by evaporating the extracting agent loaded after the extraction, are collectively referred to below as "extract fraction A". The constituents remaining in the water-containing phase are collectively referred to as "extract fraction B".

The extract fraction A according to the invention is characterized by the enrichment of lipophilic, or depletion of more hydrophilic compounds of the primary extract. This enrichment or depletion comes from a significantly reduced mono-CCS portion and a greatly reduced mono-

CCS / flavonoid quotients expressed (see Figure 1 and comparison Table 3 with 7). A total CCS content of at least 6%, usually from 10 to 30% when using aqueous primary extracts and at least 6%, preferably at least 10%, particularly preferably 15-50% when using alcoholic / aqueous primary extracts can be found , The mono-CCS share of the total CCS of this fraction is below 30%, e.g., regardless of the type of primary extractant. 3 to 30%, preferably 10 to 30% depleted compared to the primary extract. The flavonoid content of the

Extract fraction A is at least 3%, for example at least for aqueous and for alcoholic / aqueous primary extracts, preferably 7 to 20% for aqueous and alcoholic / aqueous primary extracts. According to the invention, the mono-CCS / flavonoid quotient of fraction A is reduced to values less than 1 compared to aqueous and alcoholic / aqueous primary extracts.

The extract fraction B according to the invention is distinguished by the depletion of lipophilic or the addition of more hydrophilic compounds. This depletion or enrichment is expressed by a significantly increased mono-CCS portion and a greatly increased mono-CCS / flavonoid quotient (see Figure 1 and comparison of Table 3 with 7).

Total CCS contents of at least 1% are found, usually from 2 to 10% when using aqueous primary extracts and usually 3 to 15% when using alcoholic / aqueous primary extracts. The mono CCS share of the total CCS share is at least 70%, e.g. increased at least 75% and mostly over 75% to 85%. The flavonoid content of the

Extract fraction B is at most 2%, preferably 0.02 to 1.5% for aqueous and alcoholic / aqueous primary extracts. The mono-CCS / flavonoid ratio of fraction B is increased to values between 4 and 35 compared to the primary extract regardless of the primary extractant, e.g. between 5 and 35.

Exemplary results of four fractionations according to the invention of primary extracts from high-quality drugs (Examples 8 to 11) are listed in Table 7.

The extractant in the processes according to the invention is a non-aqueous extractant, such as an organic solvent. Examples include alcohols, ketones, esters, ethers, aromatics, etc. Aliphatic alcohols and carboxylic acid esters are particularly suitable. These solvents can be used alone or as a mixture of the above compounds. In a particularly preferred In one embodiment, a mixture of 2-butanol and ethyl acetate is used as the extracting agent.

In a preferred embodiment of the method, the comminuted drug is extracted with water. The volume of the primary extract can then be reduced to about half in vacuo and is extracted at room temperature with a mixture of 2-butanol and ethyl acetate. The fraction soluble in the organic phase is separated off and evaporated to dryness (fraction A). The extract contains the amounts of CCS derivatives and flavonoids described above as well as other, unidentified substances. The remaining water-containing fraction is also dried (fraction B) ~.

In another preferred embodiment of the method, the comminuted drug is first extracted with an alcoholic / aqueous extracting agent (primary extract). The primary or secondary alcohols have the chain length from CI to C4. disturbing

Plant components (e.g. chlorophylls, waxes) of the alcoholic-aqueous primary extracts are extracted from the concentrated water-containing phase with suitable, water-immiscible, non-polar organic solvents such as e.g. Hexane, petroleum ether or dichloroethane removed by extraction. The aqueous phase (primary extract) is extracted at room temperature with a mixture of 2-butanol and ethyl acetate. The fraction soluble in the solvent mixture is separated off and evaporated to dryness (fraction A). The extract contains those described above

Amounts of CCS derivatives and flavonoids as well as other, unidentified substances. The remaining water-containing fraction is also dried (fraction B).

The extract fractions A and B differ significantly in the content and composition of the CCS and the flavonoids both from the corresponding parent primary extracts and generally from prior art primary extracts.

The resulting extract fractions A and B surprisingly have very different pharmacological activity profiles. Extract fraction A is a powerful inhibitor of cholesterol biosynthesis and has a very high antioxidative capacity to suppress the formation of free radicals. It has been found that the pharmacological effects are significantly higher than those of the primary extracts.

In contrast, fraction A, in contrast to the primary extract or extract fraction B, shows little or no effectiveness in a test model for dyspepsia (see Tables 4-6).

In contrast, extract fraction B has in contrast to

Primary extract has a high activity in the dyspepsia model and shows no significant inhibition of cholesterol biosynthesis. The antioxidant properties of fraction B are lower (see Tables 4-6 below).

The extracts A and B described can be processed and applied in customary solid, semi-solid and liquid pharmaceutical and other dosage forms, such as e.g. in powders, solutions, suspensions, tablets, film-coated tablets, coated tablets, capsules, effervescent tablets,

Effervescent granules, chewable tablets, lozenges, suspositories, creams, ointments, gels. Common auxiliary substances can be used for the respective dosage form, e.g. Celluloses, silicas, lactose, synthetic polymers, salts, colorings, flavorings, fats, oils, tensides, water and alcohols.

Examples

The invention is explained in more detail below with the aid of examples. However, the invention is not limited to this. The contents and proportions of the particular ingredients determined were as in BRAND and WESCHTA 1991, Zeitschr. Phytother. 1991; 12: 15-21 describe, measured.

Example la

300 g of artichoke leaf drug (commercial drug A) are extracted in a 2-stage maceration at 80-90 ° C (5 hours / 3 hours) with a total of 4.5 l of water. Both eluates are combined and concentrated to a volume of 2.5 l. The CCS and flavonoid contents were determined according to BRAND and WESCHTA 1991, Zeitschr. Phytother. 1991; 12: 15-21. The results are shown in Tables 2 and 3.

Examples 2a and 3a

The commercial drugs B and C are treated analogously to example la and the contents are determined accordingly. The results are shown in Tables 2 and 3.

Example lb

300 g artichoke leaf drug (commercial drug A) are per 5 hours in 55-60 ° C with 5 1

Methanol / water (80/20 V / V) extracted. The eluates are pooled. The total eluate is concentrated to about 1/3 of its volume, diluted 1: 1 (V / V) with water and then washed 3 times with 500 ml of dichloromethane. The organic phase is discarded. The CCS and flavonoid contents of the aqueous phase were determined according to BRAND and WESCHTA 1991, Zeitschr. Phytother. 1991; 12: 15-21. The results are shown in Tables 2 and 3.

Examples 2b and 3b O 03/013562

15

The commercial drugs B and C are treated analogously to Example 1b and the contents are determined accordingly. The results are shown in Tables 2 and 3.

Example 4

300 g artichoke leaf drug are extracted in a 2-stage maceration at 80-90 ° C (5 hours / 3 hours) with a total of 4.5 l of water. Both eluates, which together contain approx. 124 g dry substance, are combined and combined into one

Volume of 2.5 1 concentrated. The CCS and flavonoid contents were determined according to BRAND and WESCHTA 1991, Zeitschr. Phytother. 1991; 12: 15-21. The results are in the table

2 and 3.

Example 5

300 g of artichoke leaf drug from another batch (batch 2) are extracted in a 2-stage maceration at 80-90 ° C (5h / 3h) with a total of 4.5 l of water. Both eluates, which together contain approx. 121 g dry extract, are combined and concentrated to a volume of 2.5 l. The CCS and flavonoid contents were determined according to BRAND and WESCHTA 1991, Zeitschr. Phytother. 1991; 12: 15-21. The results are shown in Tables 2 and 3.

Example 6

300 g artichoke leaf drug are extracted in 5 hours perculation at 55-60 ° C with 5 1 methanol / water (80/20 V / V). The eluates are pooled. Together they contain 108 g dry matter. The total eluate is concentrated to about 1/3 of its volume, diluted 1: 1 (V / V) with water and then washed 3 x 500 ml dichloromethane. The organic phase is discarded. The aqueous phase contains 86 g dry residue. The CCS and flavonoid contents were determined according to BRAND and WESCHTA 1991, Zeitschr. Phytother. 1991; 12: 15-21 determined. The results are shown in Tables 2 and 3.

Example 7

300 g artichoke leaf drug (batch 2) are extracted in a five-hour perculation at 55-60 ° C with 5 1 methanol / water (80/20 V / V). The eluates are pooled. Together they contain 85 g of dry extract. The total eluate is concentrated to about 1/3 of its volume, diluted 1: 1 (V / V) with water and then washed 3 times with 500 ml of dichloromethane. The organic phase is discarded. The aqueous phase contains 71 g dry residue. The CCS and flavonoid contents were determined according to BRAND and WESCHTA 1991, Zeitschr. Phytother. 1991; 12: 15-21. The results are shown in Tables 2 and 3.

Table 2: Influence of drug quality and the choice of extracting agent on CCS and flavonoid levels in various drug and the resulting extract batches (examples of commercial commercial drugs A, B and C as well as high-quality starting drugs)

The CCS and flavonoid levels of primary artichoke leaf extracts depend on the levels of the starting drug and the choice of extracting agent. High-quality artichoke leaf drug can contain 1 to 7% CCS and 0.2 to 1.2% flavonoids, depending on the variety, origin, harvest time, growing, drying and storage conditions, with the mono-CCS accounting for 40 to 60% of the total Make CCS salary. In Table 2 and 3 are results of

Studies on primary extracts, made from qualitatively different drugs with different extracting agents, are listed. The CCS content of aqueous extracts is a maximum of 11% and that of methanolic aqueous maximum 20%. The flavonoid content of aqueous extracts can be up to 2.5% and for alcoholic / aqueous extracts up to 3%.

Table 3: Share of mono-CCS in total CCS contents and mono-CCS / flavonoid quotient in various drug and associated extract batches (examples of commercial commercial drugs A, B and C and high-quality starting drugs)

The mono-CCS portion of the total CCS content can vary between 49 and 65% for aqueous and between 44 and 59% for methanolic / aqueous extracts. The mono-CCS / flavonoid quotient in the extract is in the range from 2.0 to 3.2 when extracted with water and when extracted with Methanol / water between 2.0 and 2.7. Both parameters reflect the relationships of the starting drug almost exactly (Table 3). It should therefore be noted that both aqueous and aqueous / alcoholic extracts have a roughly identical quality compared to each other and to the starting drug.

Example 8

Following the primary extraction according to Example 4, there is a five-time liquid-liquid extraction, each with 600 ml of ethyl acetate / 2-butanol (60/40 V / V), each for 3 to 5 minutes at room temperature. The organic phases are combined, concentrated to dryness in vacuo at 40 ° C., then dried in vacuo at 60 ° C. for 2 hours. 18.65 g of dry extract are obtained (extract fraction A).

The organically extracted aqueous lower phase is concentrated in vacuo at 40 ° C and dried in vacuo at 60 ° C for 2 h. 93.45 g of dry extract are obtained (extract fraction B).

Example 9

Following the primary extraction according to Example 5, there is a five-time liquid-liquid extraction, each with 600 ml of ethyl acetate / 2-butanol (60/40 V / V) for 3 to 5 minutes at room temperature. The organic phases are combined, concentrated to dryness in vacuo at 40 ° C., then dried in vacuo at 60 ° C. for 2 hours. 11 g of dry extract are obtained (extract fraction A)

The organically extracted aqueous lower phase is concentrated in vacuo at 40 ° C. and dried in vacuo at 60 ° C. for 2 hours. 96 g of dry extract are obtained (extract fraction B). Example 10

The aqueous phase of Example 6 is concentrated in vacuo to about a 1/3 of its volume and extracted five times with 500 ml of ethyl acetate / 2-butanol (60/40 V / V) each for 3 to 5 min at room temperature. The organic phases are combined. The solvent is removed in vacuo at 40 ° C. The residue is then dried in vacuo at 60 ° C. for 2 h. 16 g of dry extract are obtained (extract fraction A).

The organically extracted aqueous lower phase is concentrated in vacuo at 40 ° C and then dried in vacuo at 60 ° C for 2 h. 61 g of dry extract are obtained (extract fraction B)

Example 11

The aqueous phase of Example 7 is concentrated in vacuo to about 1/3 of its volume and extracted five times with 500 ml of ethyl acetate / 2-butanol (60/40 V / V) each for 3 to 5 min at room temperature. The organic phases are combined. The solvent was removed in vacuo at 40 ° C. The residue is then dried in vacuo at 60 ° C. for 2 hours. 11 g of dry extract are obtained (extract fraction A)

The organically extracted aqueous lower phase is concentrated in vacuo at 40 ° C. and then dried in vacuo at 60 ° C. for 2 hours. 57 g of dry extract are obtained (extract fraction B).

Pharmacological examinations:

Inhibition of cholesterol biosynthesis

The inhibition of cholesterol biosynthesis was determined according to MERTENS K. et al. , Toxic. in vitro 1993; 7: 439-441. 21

Table 4: Inhibition of cholesterol biosynthesis in rat hepatocytes at an applied concentration of 0.1 mg / ml and 1.0 mg / ml

Antioxidant capacity

The antioxidative capacity was determined according to GUGELER N., peroxidation reactions in artherogenesis: modulators of LDL oxidation and radical formation of macrophages, dissertation 1997, Faculty of Biology at the University of Tübingen, Germany. Table 5: Inhibition of horseradish peroxidase and xanthine oxidase at an applied concentration of 0.3 μg / batch

Anti-dyspeptic effect

The determinations on the antidyspeptic effect were carried out according to BONISCH H. et al. , Brit. J. Pharmacol. 1993; 108: 436-442. Table 6: ¹⁴ C-guanidinium uptake in neuroblastoma cells after application of various test substances

Table 7: Mono-, di- and total CCS and flavonoid contents of the primary extracts and the associated extract fractions from Examples 4 to 11

Claims

claims

1. Artichoke leaf extract (Cynarae folium), containing:

A total CCS content of mono-CCS and di-CCS of at least 6%, preferably 10 to 50% based on the total amount of the extract, a flavonoid content of at least 3%, preferably 4%, preferably 7 to 30% based on the total amount of the extract.

2. Extract according to claim 1, with a proportion of mono-CCS of less than 30%, preferably 3 to 30%, particularly preferably 10 to 30%, based on the total CCS content.

3. Extract according to claim 1 or 2, with a ratio of mono-CCS content to flavonoid content of less than 1.

4. Process for making an extract from

Artichoke leaves (Cynarae folium) according to claims 1 to 3, comprising the steps:

Liquid-liquid extraction of a primary extract from fresh or dried

Artichoke leaves obtained by extraction with water or by extraction with an organic solvent from the series of alcohols, ketones, esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a non-aqueous, organic solvent from the series of alcohols , Ketones, esters, ethers, aromatics or mixtures of these compounds, and recovery of the organic phase

5. The method according to claim 4, wherein the organic

Solvent for extracting the primary extract is a mixture of 2-butanol and ethyl acetate.

6. The method according to claim 4 or 5, comprising the upstream steps:

Concentrate the primary extract volume, or add water to the primary extract until the extract contains over 50% water. Washing the extract with a non-polar, water-immiscible solvent, preferably one from the series of alkanes, alkenes, ethers, esters or chlorinated hydrocarbons; Separation and discarding of the organic phase.

7. Artichoke leaf extract (Cynarae folium), containing:

A total CCS content of mono-CCS and Di-CCS of at least 1%, preferably 2 to 15% based on the total amount of the extract, a flavonoid content of at most 2%, preferably 0.02 to 1.5% based on the total amount of the extract, a proportion of mono-CCS of at least 70%, preferably at least 75%, based on the total CCS content.

8. Extract according to claim 7, with a ratio of mono-CCS content to flavonoid content between 4 and 35, preferably 5 to 35.

9. Process for making an extract from

Artichoke leaves (Cynarae folium) according to claim 7 or 8, comprising the steps

Liquid-liquid extraction of a primary extract from fresh or dried artichoke leaves, obtained by extraction with

Water or by extraction with an organic solvent from the series of alcohols, ketones, Esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a non-aqueous, organic solvent from the series of alcohols, ketones, esters, ethers, aromatics or mixtures of these compounds, and

Obtaining the aqueous phase.

10. The method according to claim 9, wherein the organic solvent for extracting the primary extract is a mixture of 2-butanol and ethyl acetate.

11. The method according to claim 9 or 10, comprising the upstream steps:

Concentrate the primary extract volume, or add water to the primary extract until the extract is over

Contains 50% water,

Washing the extract with a non-polar, water-immiscible solvent, preferably one from the series of alkanes, alkenes, ethers, esters or chlorinated hydrocarbons;

Separation and discarding of the organic phase.

12. Use of the extracts according to one of claims 1 to 3 and 7 to 8 for the manufacture of medicaments.

13. Use of the extracts according to one of claims 1 to 3 and 7 to 8 for the production of foods.

14. Use of the extracts according to one of claims 1 to 3 and 7 to 8 for the preparation of dietary

Food.

15. Use of the extracts according to one of claims 1 to 3 and 7 to 8 for the production of cosmetics.

16. Use of the extracts according to one of claims 1 to 3 for the production of a preparation according to claims 12 to 15 with antioxidative, cell and organ protective action.

17. Use of the extract according to one of claims 1 to

3 for the preparation of a preparation according to claims 12 to 15 for the treatment and prophylaxis of hypercholesterolemia and hyperlipidemia. -

18. Use of the extract according to one of claims 1 to

3 for the preparation of a preparation according to claims 12 to 15 for the treatment and prophylaxis of cardiovascular diseases and atherosclerosis.

19. Use of the extract according to one of claims 1 to

3 for the preparation of a preparation according to claims 12 to 15 for the treatment and prophylaxis of dementia.

20. Use of the extract according to one of claims 7 to

8 for the preparation of a preparation according to claims 12 to 15 with antiserotonergic, spasmolytic, anticholestatic, choleretic, antiemetic, prokinetic effect.

21. Use of the extract according to one of claims 7 to

8 for the preparation of a preparation according to claims 12 to 15 for increasing vesicular secretion and fat digestion, for the treatment of dyspepsia and for the treatment of IBS (Irretable Bowl Syndrome).